Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study
Open Access
- 8 September 2011
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 1-9
Abstract
Exercise interventions during adjuvant cancer therapy have been shown to increase functional capacity, relieve fatigue and distress and may assist rates of chemotherapy completion. These studies have been limited to breast, gastric and mixed cancer groups and it is not yet known if a similar intervention is even feasible among women with ovarian cancer. We aimed to assess safety, feasibility and potential effect of a walking intervention in women undergoing chemotherapy for ovarian cancer. Women newly diagnosed with ovarian cancer were recruited to participate in an individualised walking intervention throughout chemotherapy and were assessed pre- and post-intervention. Feasibility measures included session adherence, compliance with exercise physiologist prescribed walking targets and self-reported program acceptability. Changes in objective physical functioning (6-minute walk test), self-reported distress (Hospital Anxiety and Depression Scale), symptoms (Memorial Symptom Assessment Scale - Physical) and quality of life (Functional Assessment of Cancer Therapy - Ovarian) were calculated, and chemotherapy completion and adverse intervention effects recorded. Seventeen women were enrolled (63% recruitment rate). Mean age was 60 years (SD = 8 years), 88% were diagnosed with FIGO stage III or IV disease, 14 women underwent adjuvant and three neo-adjuvant chemotherapy. On average, women adhered to > 80% of their intervention sessions and complied with 76% of their walking targets, with the majority walking four days a week at moderate intensity for 30 minutes per session. Meaningful improvements were found in physical functioning, physical symptoms, physical well-being and ovarian cancer-specific quality of life. Most women (76%) completed ≥85% of their planned chemotherapy dose. There were no withdrawals or serious adverse events and all women reported the program as being helpful. These positive preliminary results suggest that this walking intervention for women receiving chemotherapy for ovarian cancer is safe, feasible and acceptable and could be used in development of future work. ACTRN12609000252213Keywords
This publication has 27 references indexed in Scilit:
- Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphomaJournal of Experimental & Clinical Cancer Research, 2009
- Australian Association for Exercise and Sport Science position stand: Optimising cancer outcomes through exerciseJournal of Science and Medicine in Sport, 2009
- Physical activity preferences of ovarian cancer survivorsPsycho-Oncology, 2009
- The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary diseaseHealth and Quality of Life Outcomes, 2008
- Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancerAnnals of Oncology, 2007
- Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Clinical significance of patient-reported questionnaire data: another step toward consensusJournal of Clinical Epidemiology, 2005
- The group psychotherapy and home‐based physical exercise (group‐hope) trial in cancer survivors: Physical fitness and quality of life outcomesPsycho-Oncology, 2003
- Depression, Anxiety, and Quality of Life in Patients with Epithelial Ovarian CancerGynecologic Oncology, 2000
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983